Torigen Pharmaceuticals, a commercial-stage animal health company in Farmington, announced Wednesday it had closed on a $13 million round of venture capital financing.
The Series A1 round, led by Werth Family Investment Associates and Connecticut Innovations, brings the total amount raised by the company to $18 million.
Ashley Kalinauskas, CEO and co-founder of Torigen Pharmaceuticals, said the infusion of money will allow the company to continue developing new products to help pets diagnosed with cancer and other immune diseases.
“Our goal is to create the industry’s first oncology toolbox for veterinarians,” Kalinauskas said.
Torigen produces an experimental autologous cancer immunotherapy, a type of individualized treatment that uses the animal’s own tumor cells to create an anti-tumor immune response.
Existing investors Emerald Development Managers, Gaingels, Kema Fund, University of Notre Dame, SoGal Ventures and UCONN Innovation Fund participated in the new round of financing. New investors included Ironwood Capital and Advantage Capital.